Contact Us

Vaccine

  1. Home
  2. Market Insights

Europe healthcare regulator recommends redmsivir for use on Covid19 patients.

Via Medscape Central African Republic
The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc's antiviral treatment, remdesivir, for use in COVID-19 patients, making it the first treatment to be on track to be green-lit in the continent.The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug's use in adults and adolescents from 12 years of age with pneumonia who require oxygen support. (https://bit.ly/3i3O6Ck)Remdesivir has already been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees ($66.13-$79.35).

Source: Medscape